KOVALTRY® is manufactured using state-of-the-art techniques1,2

20 years

KOVALTRY® has a FVIII primary protein structure that has been in use for more than 20 years1

Recombinant Factor VIII product

KOVALTRY® is an unmodified, full length rFVIII product. Post-translational modifications are similar to those of natural FVIII1


Human heat shock protein 70 (HSP70), a chaperone protein, was introduced intracellularly to improve proper folding of the FVIII protein1

KOVALTRY® manufacturing process

Human- and animal-derived raw materials are not added in the cell culture, purification, or formulation processes1

20-nm filtration

20-nm filtration step designed to remove potential small viruses1


KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY® is not indicated for the treatment of von Willebrand disease.


KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY®. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY® if symptoms occur and seek immediate emergency treatment.

KOVALTRY® may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation can occur following administration of KOVALTRY®. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY® is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥3%) were headache, pyrexia, and pruritus.

For additional important risk and use information, please see full Prescribing Information.

References: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2016. 2. Garger S, Wu P, Regan L, et al. BAY 81-8973: A full-length, unmodified, recombinant human factor VIII product created through advanced manufacturing technologies. Poster presented at: European Association for Haemophilia and Allied Disorders 9th Annual Congress; February 2016; Malmö, Sweden.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© 2017 Bayer. All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer. Bayer Access Solutions is a service mark of Bayer.

Site Last Modified 06/2017